4-butyrolactone has been researched along with Degenerative Disc Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M; Luo, L; Shi, C; Wang, Y; Wang, Z; Wu, J; Zhang, C; Zhou, Y; Zuo, R | 1 |
| Chen, J; Chen, T; Chen, Y; Lin, J; Shao, Z; Sheng, S; Wang, K; Wang, X; Xu, T; Ying, X; Zhang, Z | 1 |
2 other study(ies) available for 4-butyrolactone and Degenerative Disc Disease
| Article | Year |
|---|---|
Kinsenoside ameliorates intervertebral disc degeneration through the activation of AKT-ERK1/2-Nrf2 signaling pathway.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Intervertebral Disc; Intervertebral Disc Degeneration; Mitochondria; Monosaccharides; NF-E2-Related Factor 2; Nucleus Pulposus; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction | 2019 |
Ligustilide alleviated IL-1β induced apoptosis and extracellular matrix degradation of nucleus pulposus cells and attenuates intervertebral disc degeneration in vivo.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents; Apoptosis; Cells, Cultured; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Extracellular Matrix; Humans; Inflammation Mediators; Interleukin-1beta; Intervertebral Disc Degeneration; NF-kappa B; Nitric Oxide Synthase Type II; Nucleus Pulposus; Proteolysis; Rats; Rats, Sprague-Dawley; Signal Transduction | 2019 |